Bibliografia Sclerosi Multipla

La seguente bibliografia è relativa all’articolo “Sclerosi multipla: terapie naturali“.

1. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R BENEFIT Study Group.
   Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
   2007 Aug 4;370(9585):389-97
2. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.
   Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
   Lancet Neurol. 2009 Nov;8(11):987-97.
3. Ransohoff RM.
   Natalizumab for multiple sclerosis.
   N Engl J Med. 2007 Jun 21;356(25):2622-9. Review.
4. Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group.
   Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
   Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54.
5. Cadavid D, Jurgensen S, Lee S.
   Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
   PLoS One. 2013;8(1):e53297.
6. Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami.
   Summary of evidence-based guideline: complementary and alternative medicine in        multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.
   2014 Mar 25;82(12):1083-92
7. s VB, Cesarik M, Matovina LZ, Zavoreo I, Corić L, Drnasin S, Demarin V.
   The role of complementary and alternative medicine in therapy of multiple sclerosis.
   Acta Clin Croat. 2013 Dec;52(4):464-71.
8. Kochs L, Wegener S, Sühnel A, Voigt K, Zettl UK.
   The use of complementary and alternative medicine in patients with multiple sclerosis: a longitudinal study.
   Complement Ther Med. 2014 Feb;22(1):166-72.
9. Swank RL.
   Treatment of multiple sclerosis with low-fat diet: result of seven years of experience.
   Ann Intern Med. 1956;45:812
10. Swank RL, Bourdillon RB.
    Multiple sclerosis: assessment of treatment with a modified low-fat diet.
    J Nerv Ment Dis. 1960;131:468–88
11. Swank RL
    Multiple sclerosis: twenty years on low fat diet.
    Arch Neurol. 1970;23:46074
12. Swank RL, Grimsgaard A.
    Multiple sclerosis: the lipid relationship.
    Am J Clin Nutr. 1988;48:1387–93
13. Swank RL.
    Multiple sclerosis: fat-oil relationship.
    1991;7:368–76
14. Swank RL, Dugan BB.
    Effect of low saturated fat diet in early and late cases of multiple sclerosis.
    1990;336:37–9
15. Swank RL, Goodwin J.
    Review of MS patient survival on a Swank low saturated fat diet.
    2003;19:161–2
16. Nordvik I, Myhr KM, Nyland H, Bjerve KS.
    Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients.
    Acta Neurol Scand. 2000;102:143–9
17. Weinstock-Guttman B, Baier M, Park Y, et al.
    Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients.
    Prostaglandins Leukot Essent Fatty Acids. 2005;73:397–404
18. Malosse D, Perron H, Sasco A, et al.
    Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study.
    Neuroepidemiology 1992; 11:304-312.
19. Malosse D, Perron H.
    Correlation analysis between bovine population, other farm animals,house pets, and multiple sclerosis prevalence.
    Neuroepidemiology 1993; 12:15-27.
20. Schwarz S1, Knauth M, Schwab S, Walter-Sack I, Bonmann E, Storch-Hagenlocher B.
    Acute disseminated encephalomyelitis after parenteral therapy with herbal extracts: a report of two cases.
    J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):516-8.
21. Namjooyan F1, Ghanavati R2, Majdinasab N3, Jokari S4, Janbozorgi M5.
    Uses of complementary and alternative medicine in multiple sclerosis.
    J Tradit Complement Med. 2014 Jul;4(3):145-52.
22. Kostianovsky A1, Maskin P, Noriega MM, Soler C, Bonelli I, Riley CS, O’Connor KC, Saubidet CN, Alvarez PA.
    Acute demyelinating disease after oral therapy with herbal extracts.
    Case Rep Neurol. 2011 May;3(2):141-6.
23. Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, Whitham R.
    American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study.
    Mult Scler. 2011 Dec;17(12):1523-6.
24. Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, Adams J, Stover T, Sangeorzan A, Sloan A, Howieson D, Wild K, Haselkorn J, Bourdette D.
    Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial.
    2012 Sep 18;79(12):1278-84.
25. Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, Wild K, Oken B, Whitham R, Bourdette D.
    Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial.
    Mult Scler. 2007 Apr;13(3):376-85. Epub 2007 Jan 29.
26. Boveris A, Valdez L, Alverez S.
    Inhibition by wine polyphenols of peroxynitriteinitiated chemiluminescence and NADH oxidation.
    Ann N Y Acad Sci. 2002;957:90–102.
27. CamposEsparza,MR, SanchezGomez,MV, Matute C.
    Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols
    Cell Calcium. 2009;45:358–68.
28. Zhu Q, Zheng ZP, Cheng KW, Wu JJ, Zhang S, Tang YS, et al
    Natural polyphenols as direct trapping agents of lipid peroxidationderived acrolein and 4hydroxytrans2nonenal.
    Chem Res Toxicol. 2009;22:1721–7.
29. Miadenka P, Macakova K, Filipsky T, Zatloukalova L, Jahodaf L, Bovicelli P, et al.
    In vitro analysis of iron chelating activity of flavonoide.
    J Inorg Biochem. 2011;105:693–701.
30. Bhullar KS, Rupasinghe HP.
    Polyphenols: multipotent therapeutic agents in neurodegenerative diseases.
    Oxid Med Cell Longev. 2013;2013:891748.
31. Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, Munschauer F.
    Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients.
    J Neuroimmunol. 2008;205:142–147.
32. Sternberg Z, Chadha K, Lieberman A, Drake A, Hojnacki D, Weinstock-Guttman B, Munschauer F.
    Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta.
    J Neuroinflammation. 2009 Oct 13;6:28
33. Theoharides TC.
    Mast cells: the immune gate to the brain.
    Life Sci.1990;46:607–617.
34. Zappulla JP, Arock M, Mars LT, Liblau RS.
    Mast cells: new targets for multiple sclerosis therapy?
    J Neuroimmunol.2002;131:5–20.
35. Theoharides TC, Cochrane DE.
    Critical role of mast cells in inflammatory diseases and the effect of acute stress.J Neuroimmunol. 2004;146:1–12.
36. kim KS1, Wass CA, Cross AS, Opal SM.
    Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat
    Lymphokine Cytokine Res. 1992 Dec;11(6):293-8.
37. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P,       McDonald WI.
    Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.
    1990 Oct;113 ( Pt 5):1477-89.
38. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC.
    Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress.
    J Pharmacol Exp Ther. 2002 Dec;303(3):1061-66
39. Tai Z, Lin Y, He Y, Huang J, Guo J, Yang L, Zhang G, Wang F.
    Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Cell Signal. 2014 Mar;26(3):619-28.
40. Edwards R.L., Lyon T., Litwin S.E., Rabovsky A., Symons J.D., Jalili T.
    Quercetin reduces blood pressure in hypertensive subjects.
    Nutr.2007;137:2405–2411.
41. Egert S., Bosy-Westphal A., Seiberl J., Kurbitz C., Settler U., Plachta-Danielzik S., Wagner A.E., Frank J., Schrezenmeir J., Rimbach G., et al.
    Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study.
    J. Nutr. 2009;102:1065–1074.
42. Angeloni C., Leoncini E., Malaguti M., Angelini S., Hrelia P., Hrelia S.
    Role of quercetin in modulating rat cardiomyocyte gene expression profile.
    J. Physiol. Heart Circ. Physiol.
43. Chirumbolo S.
    Role of quercetin in vascular physiology.
    J. Physiol. Pharmacol. 2012;90:1652–1657
44. Khoo N.K., White C.R., Pozzo-Miller L., Zhou F., Constance C., Inoue T., Patel R.P., Parks D.A. Dietary flavonoid quercetin stimulates vasorelaxation in aortic vessels.
    Free Radic. Biol. Med. 2010;49:339–347.
45. Perez-Vizcaino F., Duarte J., Jimenez R., Santos-Buelga C., Osuna A.
    Antihypertensive effects of the flavonoid quercetin.
    Rep. 2009;61:67–75.
46. Larson A.J., Symons J.D., Jalili T.
    Quercetin A treatment for hypertension?A review of efficacy and mechanisms. 2010;3:237–250
47. Larson A.J., Symons J.D., Jalili T. Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy. Adv. Nutr. 2012;3:39–46.
48. Mozzicafreddo M., Cuccioloni M., Bonfili L., Eleuteri A.M., Fioretti E., Angeletti M.
    Antiplasmin activity of natural occurring polyphenols.
    Biophys. Acta. 2008;1784:995–1001
49. Mosawy S., Jackson D.E., Woodman O.L., Linden M.D.
    Treatment with quercetin and 3′,4′-dihydroxyflavonol inhibits platelet function and reducesthrombus formationin vivo.
    Thromb. Thrombolysis. 2012;36:50–57.
50. Perez-Vizcaino F., Bishop-Bailley D., Lodi F., Duarte J., Cogolludo A., Moreno L., Bosca L., Mitchell J.A., Warner T.D.
    The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells.
    Biophys. Res. Commun. 2006;346:919–925.
51. Yoshizumi M., Tsuchiya K., Suzaki Y., Kirima K., Kyaw M., Moon J.H., Terao J., Tamaki T.
    Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway.
    Biophys. Res. Commun. 2002;293:1458–1465.
52. Qin T.C., Chen L., Yu L.X., Gu Z.L.
    Inhibitory effect of quercetin on cultured neonatal rat cardiomyocytes hypertrophy induced by angiotensin.
    Acta Pharmacol. Sin. 2001;22:1103–1106.
53. Jalili T., Carlstrom J., Kim S., Freeman D., Jin H., Wu T.C., Litwin S.E., David Symons J. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction.
    Cardiovasc. Pharmacol. 2006;47:531–541.
54. Kao TK1, Ou YC, Raung SL, Lai CY, Liao SL, Chen CJ.
    Inhibition of nitric oxide production by quercetin in endotoxin/cytokine-stimulated microglia.
    Life Sci. 2010 Feb 27;86(9-10):315-21.
55. Sharma V1, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, Sen E.
    Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection.
    Brain Res Bull. 2007 Jun 15;73(1-3):55-63. Epub 2007 Feb 28.
56. Kempuraj D1, Castellani ML, Petrarca C, Frydas S, Conti P, Theoharides TC, Vecchiet J.
    Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line
    Clin Exp Med. 2006 Dec;6(4):150-6.
57. Abramov AY1, Jacobson J, Wientjes F, Hothersall J, Canevari L, Duchen MR.
    Expression and modulation of an NADPH oxidase in mammalian astrocytes.
    J Neurosci. 2005 Oct 5;25(40):9176-84.
58. Bureau G1, Longpré F, Martinoli MG.
    Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation.
    J Neurosci Res. 2008 Feb 1;86(2):403-10.
59. Martino G1, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M.
    Inflammation in multiple sclerosis: the good, the bad, and the complex.
    Lancet Neurol. 2002 Dec;1(8):499-509.
60. Muthian G1, Bright JJ.
    Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte.
    J Clin Immunol. 2004 Sep;24(5):542-52.
61. Procaccini C1, De Rosa V2, Pucino V3, Formisano L4, Matarese G5.
    Animal models of Multiple Sclerosis.
    Eur J Pharmacol. 2015 Mar 27.
62. Verbeek R, van Tol EA, van Noort JM.
    Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice.
    Biochem Pharmacol. 2005 Jul 15;70(2):220-8.
63. Muthian G, Bright JJ.
    Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte.
    J Clin Immuno. 2004 Sep;24(5):542-52.
64. Imler TJ Jr1, Petro TM.
    Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.
    Int Immunopharmacol. 2009 Jan;9(1):134-43.
65. Hendriks JJ, de Vries HE, van der Pol SM, van den Berg TK, van Tol EA, Dijkstra CD.
    Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study.
    Biochem Pharmacol. 2003 Mar 1;65(5):877-85.
66. Guo Y, Mah E, Davis CG, Jalili T, Ferruzzi MG, Chun OK, Bruno RS.
    Dietary fat increases quercetin bioavailability in overweight adults.
    Mol Nutr Food Res. 2013 May;57(5):896-905.
67. Jin F, Nieman DC, Shanely RA, Knab AM, Austin MD, Sha W.
    The variable plasma quercetin response to 12-week quercetin supplementation in humans.
    Eur J Clin Nutr. 2010 Jul;64(7):692-7.
68. Cialdella-Kam L, Nieman DC, Sha W, Meaney MP, Knab AM, Shanely RA.
    Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults.
    Br J Nutr. 2013 Jun;109(11):1923-33.
69. Bengmark S.
    Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase2,lipooxygenase, andinducible nitric oxide synthase inhibitor: A shield against acute and chronic diseases.
    JPEN J Parenter Enteral Nutr.2006;30:45–51.
70. Amor S, Baker D, Van der Valk P.
    Inflammation in neurodegenerative disease.
    2010;129:154–69
71. Aggarwal BB1, Harikumar KB
    Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.
    Int J Biochem Cell Biol. 2009 Jan;41(1):40-59.
72. Aggarwal S1, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB.
    Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
    Mol Pharmacol. 2006 Jan;69(1):195-206. Epub 2005 Oct 11.
73. Singh S, Aggarwal BB.
    Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B.
    J Biol Chem. 1995 May 5;270(18):10631-9.
74. Xie L, Li XK, Takahara S.
    Curcumin has bright prospects for the treatment of multiple sclerosis.
    Int Immunopharmacol. 2011 Mar;11(3):323-30.
75. Seyedzadeh MH, Safari Z, Zare A, Gholizadeh Navashenaq J, Razavi SA, Kardar GA, Khorramizadeh MR.
    Study of curcumin immunomodulatory effects on reactive astrocyte cell function.
    Int Immunopharmacol. 2014 Sep;22(1):230-5.
76. Tegenge MA, Rajbhandari L, Shrestha S, Mithal A, Hosmane S, Venkatesan A.
    Curcumin protects axons from degeneration in the setting of local neuroinflammation.
    Exp Neurol. 2014 Mar;253:102-10.
77. Natarajan C, Bright JJ.
    Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes.
    J Immunol. 2002 Jun 15;168(12):6506-13.
78. Xie L1, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, Isaka Y, Takahara S.
    Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production.
    Int Immunopharmacol. 2009 May;9(5):575-81.
79. Chearwae W1, Bright JJ.
    15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte.
    J Clin Immunol. 2008 Sep;28(5):558-70.
80. Kanai M1.
    Therapeutic applications of curcumin for patients with pancreatic cancer.
    World J Gastroenterol. 2014 Jul 28;20(28):9384-91.
81. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation.
    BMC Complement Altern Med. 2006;6:10.
82. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects.
    Cancer Epidemiol Biomarkers Prev. 2008;17:1411–1417.
83. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
    Cancer Epidemiol Biomarkers Prev. 2005;14:120–125.
84. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer.
    Clin Cancer Res. 2008;14:4491–4499.
85. Jagetia GC, Aggarwal BB.
    “Spicing up” of the immune system by curcumin.
    J Clin Immunol. 2007 Jan;27(1):19-35. Epub 2007 Jan 9.
86. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB.
    Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols.
    Arch Biochem Biophys. 2014 Oct 1;559:91-9.
87. Aggarwal BB, Gupta SC, Sung B.
    Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.
    Br J Pharmacol. 2013 Aug;169(8):1672-92.
88. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY.
    Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis.
    J Med Microbiol. 2001 Sep;50(9):812-21.
89. Dickstein JB, Moldofsky H, Hay JB.
    Brain-blood permeability: TNF-alpha promotes escape of protein tracer from CSF to blood.
    Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R148-51
90. Wright JL, Merchant RE.
    Effects of an intratumoral injection of human recombinant tumor necrosis factor-alpha on cerebrovascular permeability and leukocytic infiltration in a rat glioma model.
    Acta Neuropathol. 1997 Jan;93(1):78-86.
91. Banks WA, Plotkin SR, Kastin AJ.
    Permeability of the blood-brain barrier to soluble cytokine receptors.
    1995 May-Jun;2(3):161-5.
92. Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB.
    Cell signaling pathways and ironchelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate(EGCG)
    J Alzheimers Dis. 2008;15:211–22.
93. Mandel S, Weinreb O, Amit T, Youdim MB.
    Cell signaling pathways in the neuroprotective actions of thegreen tea polyphenols epigallocatechin 3gallate:Implications for neurodegenerativedisease.
    J Neurochem.2004;88:1555–69.
94. Mähler A, Steiniger J, Bock M, Klug L, Parreidt N, Lorenz M, Zimmermann BF, Krannich A, Paul F, Boschmann M.
    Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
    Am J Clin Nutr. 2015 Mar;101(3):487-95.
95. Sun Q, Zheng Y, Zhang X, Hu X, Wang Y, Zhang S, Zhang D, Nie H.
    Novel immunoregulatory properties of EGCG on reducing inflammation in EAE.
    Front Biosci (Landmark Ed). 2013 Jan 1;18:332-42.
96. Wang J, Ren Z, Xu Y, Xiao S, Meydani SN, Wu D.
    Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets.
    Am J Pathol. 2012 Jan;180(1):221-34.
97. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F.
    Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.
    J Immunol. 2004 Nov 1;173(9):5794-800.
98. MacMicking, J. D., D. O. Willenborg, M. J. Weidemann, K. A. Rockett, W. B. Cowden. 1992. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells.
    Exp. Med. 176:303.

Dott. Claudio Sandri